ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0970

Oxylipins Profiles During the Earliest Phases of Rheumatoid Arthritis: Associations with Clinical Stage and Treatment Outcomes

Roxana Coras1, Javier Rodríguez-Carrio2, Mercedes Alperi-López3, Patricia López4, Catalina Ulloa5, Francisco J Ballina-García3, Aaron M Armando6, Oswald Quehenberger1, Monica Guma7 and Ana Suárez4, 1University of California San Diego, La Jolla, CA, 2Department of Functional Biology, University of Oviedo, Instituto de Investigación Sanitaria del Principado de Asturias, Asturias, Spain/Bone and Mineral Research Unit, REDinREN del ISCIII, Hospital Universitario Central de Asturias, Spain, Oviedo, 3Department of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, Oviedo, 4Department of Functional Biology, University of Oviedo, Instituto de Investigación Sanitaria del Principado de Asturias, Asturias, Spain, Oviedo, 5Bone and Mineral Research Unit, REDinREN del ISCIII, Hospital Universitario Central de Asturias, Spain, Oviedo, 6Department of Pharmacology, School of Medicine, University of California, San Diego, USA, San Diego, 7Division of Rheumatology, University of California San Diego, Department of Medicine, Autonomous University of Barcelona, La Jolla, CA

Meeting: ACR Convergence 2020

Keywords: metabolomics, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: RA – Etiology & Pathogenesis (0970–0974)

Session Type: Abstract Session

Session Time: 3:00PM-3:50PM

Background/Purpose: Altered eicosanoids have been linked to rheumatoid arthritis (RA), suggesting an enhanced metabolization. Eicosanoid metabolism forms a complex network, involving different pathways and mediators, including oxylipins, which are known to modulate inflammation. However, the role of oxylipins in RA is still to be elucidated. This study aims to characterize oxylipins networks during the earliest phases of RA and evaluate their associations with clinical features. 

Methods: 60 early RA patients (2010 ACR/EULAR criteria), 11 clinically suspect arthralgia (CSA) individuals and 28 control subjects (HC) were recruited. Serum samples were collected at onset, and treatment-naïve patients (n=50) were prospectively followed-up upon csDMARD treatment.

Results: 75 oxylipins, mostly derived from arachidonic, eicosapentanoic and linoleic acids, were identified by LC-MS/MS. Differences in serum levels of 14 oxylipins across HC, CSA and RA were found, exhibiting different trajectories. Network analyses revealed strong differences in the association among oxylipins, with a clear grouping in RA and a fuzzy network with high degree and closeness found in CSA (Figure 1). PLS-DA did not provide a neat separation of groups, but cluster analysis based on oxylipins with VIP scores >1 (n=22) allowed the identification of two clusters. Cluster usage differed among groups (p=0.003) (Figure 2), and showed associations with disease severity and low rates of remission at 6 and 12 months in treatment-naïve RA (Figure 3). Pathway enrichment analyses revealed different precursors and pathways highlighting the relevance of AA and LOX pathway in CSA and RA, respectively.

Conclusion: oxylipins networks differ across stages during earliest phases of RA. Oxylipins can inform on pathways with clinical relevance for disease progression, clinical heterogeneity and treatment response.

Figure 1. Network analyses based on the concentration of oxylipins in the different study groups. Each node corresponds to a single oxylipin, numbered as per the figure legend list. Node colours represent the fatty acid precursor as follows: red (AA), green (DHA), dark blue (EPA), light blue (LA), turquoise (DHGLA), orange (ALA) (orange), magenta (OA). The lines between nodes illustrate the strength (width) and type (green: positive, red: negative) of the correlations between each pair of oxylipins. The relative position of the nodes parallels its degree of correlation that is, nodes more closely correlated locate closer to each other.

Figure 2. Heatmap and cluster analysis based on oxylipins that best separate the groups. Tiles were coloured based on concentrations, red and blue indicating high and low levels respectively, as indicated in the legend (top right). Upper bar indicates group classes (HC: blue, CSA: green, RA: red). Heatmap allowed the identification of two clusters (bottom).

Figure 3. Clinical features of RA patients based on oxylipins clusters. Variables were expressed as median (interquartile range) or n(%), unless otherwise stated. Differences were assessed by Mann-Withney or chi-square tests (or Fisher exact test, when appropriate), according to the distribution of the variables.


Disclosure: R. Coras, None; J. Rodríguez-Carrio, None; M. Alperi-López, None; P. López, None; C. Ulloa, None; F. Ballina-García, None; A. Armando, None; O. Quehenberger, None; M. Guma, None; A. Suárez, None.

To cite this abstract in AMA style:

Coras R, Rodríguez-Carrio J, Alperi-López M, López P, Ulloa C, Ballina-García F, Armando A, Quehenberger O, Guma M, Suárez A. Oxylipins Profiles During the Earliest Phases of Rheumatoid Arthritis: Associations with Clinical Stage and Treatment Outcomes [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/oxylipins-profiles-during-the-earliest-phases-of-rheumatoid-arthritis-associations-with-clinical-stage-and-treatment-outcomes/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/oxylipins-profiles-during-the-earliest-phases-of-rheumatoid-arthritis-associations-with-clinical-stage-and-treatment-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology